Bio-Thera Picks Tabuk As Stelara Biosimilar Partner In Saudi Arabia

BAT2206 Ustekinumab Biosimilar Is Already Filed In The US, EU, And China

 
• By Urtė Fultinavičiūtė

2024 was truly a dealmaking year for Bio-Thera, with the latest partnership expanding the net for its ustekinumab biosimilar.

Two people shaking hands
(Shutterstock)

More from Business

More from Deals